Stocks to watch: These large-cap stocks will be in focus Tuesday!

Stocks to watch: These large-cap stocks will be in focus Tuesday!

Indian Market
by 5paisa Research Team Last Updated: Feb 27, 2023 - 07:05 pm 215 Views

Nifty50 drops below 17,400, while Sensex finishes 176 points lower as the market continues to lose ground.

Heavyweights Infosys, TCS, and Reliance were the market's top drags, putting the most pressure on the Sensex. Nifty Midcap 100 and Nifty Smallcap 100, two broader indices, closed with respective declines of 0.7% and 1.1%. With an advance-decline ratio of 2:5, the overall market breadth was heavily in favour of the bears as 956 stocks gained and 2,593 sank at the BSE close. Notwithstanding losses experienced by their Asian counterparts, European markets started the day in the green, with the Stoxx 600 index for the entire continent climbing 0.9% as of this writing.

The Nifty50 basket's top loser, Adani Enterprises, finished the day over 10% lower. Among the other top blue-chip laggards were Bajaj Auto, UPL, Tata Steel, and Infosys. On the other hand, of the 17 gainers in the 50-scrip universe, ICICI Bank, PowerGrid, Kotak Mahindra Bank, HDFC Life, and SBI increased the most.

Watch out for these large-cap stocks in Tuesday’s trading session -

Tata Consultancy Services: The company informed the exchange that it has been recognised as a leader in Everest Group’s PEAK Matrix for procurement outsourcing. The shares of TCS have gained more than 6% in the past 6 months and it closed today at Rs 3,335 per share.

Route Mobile: The company has launched TruSense, a digital identity and security suite that is critical to securing digital transactions through a reliable ecosystem, enabling businesses to authenticate the end user in a frictionless way. The shares of Route mobile rose by nearly 15% in the last one month and it closed today at Rs 1,334 per share

Dr Reddy’s Laboratories: The company announced an agreement to acquire Mayne Pharma’s US generic prescription product portfolio. The portfolio includes approximately 45 commercial products, four pipeline products and 40 approved non-marketed products, including several generic products focused on women’s health.

How do you rate this article?

Fill in your details below:

Start Investing in 5 mins*

Rs. 20 Flat Per Order | 0% Brokerage

About the Author

Our research team is composed of some highly qualified research professionals, their expertise range across sectors.


Investment/Trading in securities Market is subject to market risk, past performance is not a guarantee of future performance. The risk of loss in trading and investment in Securities markets including Equites and Derivatives can be substantial.

Open Free Demat Account

Resend OTP
Please Enter OTP
Account belongs to

By proceeding, you agree to the T&C.

Start Investing Now!

Open Free Demat Account in 5 mins

Enter Valid Mobile Number